Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the U.S. Food and Drug Administration (FDA) has approved RADICAVA ORS® (edaravone), the ...
Target ALS today announced Merit E. Cudkowicz, Chief of the Neurology Department at Massachusetts General Hospital, as the winner of the first annual ...
Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the presentation of an analysis of real-world data that suggest continued treatment of...
Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced four presentations on amyotrophic lateral sclerosis (ALS) will be shared as part of the ...
Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that five presentations on amyotrophic lateral sclerosis (ALS) will be shared as part...
Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the U.S. Food and Drug Administration (FDA) has accepted the new drug application (NDA) ...
Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced virtual poster presentations reviewing the Phase 4 REFINE-ALS biomarker study in people ...
Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced 24-week results from the global Phase 3 open-label study evaluating the safety and...
Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced seven presentations on amyotrophic lateral sclerosis (ALS) as part of the Motor Neurone ...
Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that two abstracts on amyotrophic lateral sclerosis (ALS) will be presented during the...
Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that nearly 6,000 people with amyotrophic lateral sclerosis (ALS) in the U.S. have...
Mitsubishi Tanabe Pharma America, Inc. (MTPA) and Target ALS today announced the establishment of the inaugural Target ALS Rebecca Luker Courage...
Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that EXSERVAN™ (riluzole), the first oral film formulation of riluzole, is now...
Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced PANTHERx Rare Pharmacy has been selected as the exclusive provider of specialty...
Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced it will present findings from a new analysis of claims data from a cohort of patients...
Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the presentation of an analysis of the timing of disease progression milestones among...
Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced a post-hoc analysis of its Phase 3 edaravone study reviewing the results of intravenous ...
Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced findings from a new analysis evaluating the impact of symptom progression on the...
Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that Mitsubishi Tanabe Pharma Holdings America, Inc. (MTHA) plans to establish a new...
Mitsubishi Tanabe Pharma America, Inc. (MTPA) today celebrated its five-year anniversary of being established in the United States in 2016. MTPA has...
Mitsubishi Tanabe Pharma America, Inc. (MTPA) and Aquestive Therapeutics, Inc. (NASDAQ: AQST) today announced a licensing and supply deal for the U.S....
Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced upgrades to its out-of-pocket assistance program that aim to provide enhanced support...
Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced revisions to the REFINE-ALS biomarker study protocol to address the safety of people...
Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the initiation of a long-term safety extension study (MT-1186-A03) to the ongoing Phase ...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.